The following table shows, with respect to the Named Executive Officers, certain information concerning the grant of stock options in 1999. No stock appreciation rights were granted during 1999.

1. Each option will vest in forty-eight successive equal monthly installments over the optionee's continued service with the Company measured from the vesting start date, except as follows: the options granted to Mr. Bienaimé, the option to purchase 5,000 shares granted to Dr. Tesi, the option to purchase 6,000 shares granted to Mr. Levy, one of the options to purchase 25,000 shares granted to Dr. Tolpin and the option granted to Dr. Pouletty. These options are all on a six year vesting schedule, subject to acceleration if certain product development and financial milestones are met, with the exception of the options granted to Dr. Pouletty which vested immediately upon issuance. Each option is exercisable only with respect to vested shares.
2. Based on an aggregate of 658,262 options granted to employees and Board members in 1999, including options granted to the Named Executive Officers.
3. The exercise price may be paid in cash, in shares of Common Stock valued at fair market value on the exercise date, or through a cashless exercise procedure involving a same- day sale of the purchased shares. The Company may also finance the option exercise by lending the optionee sufficient funds to pay the exercise price for the purchased shares and the federal and state income or employment tax liability incurred by the optionee in connection with such exercise. The optionee may be permitted, subject to the approval of the Plan Administrator, to apply a portion of the shares purchased under the option (or to deliver existing shares of Common Stock) in satisfaction of such liability.
4. Potential realizable value is based on the assumption that the price per share of Common Stock appreciates at the assumed 5% and 10% annual rates of appreciation (compounded annually) over the option terms. There is no assurance that those assumed annual rates of stock price appreciation will actually be realized.
5. Dr. Tolpin resigned as Senior Vice President, Clinical Development effective April 14, 2000.

The following table sets forth information concerning option exercises and option holdings for the fiscal year ended December 31, 1999 with respect to the Named Executive Officers. Except as set forth below, no options or stock appreciation rights were exercised by any such individual during such year, and no stock appreciation rights were outstanding on December 31, 1999.

1. The options are exercisable upon vesting and are not subject to repurchase by the Company. Exercisable shares represent vested options at December 31, 1999.
2. Dr. Tolpin resigned as Senior Vice President, Clinical Development effective April 14, 2000.

Effective January 1, 1999, the non-employee directors receive an annual retainer of $15,000 paid in one (1) installment at the last Board of Directors meeting. No additional compensation is paid for meeting attendance or committee membership.

The non-employee directors also receive automatic grants of options to purchase shares of common stock pursuant to the 1996 Non-Employee Directors Stock Option Plan (the "Directors Plan"). Moreover, the Directors Plan permits non-employee directors to convert their annual cash retainer into additional options to purchase shares of common stock.

None of our executive officers have employment agreements with us, and their employment may be terminated at any time at the discretion of the Board of Directors. However, the Compensation Committee of the Board of Directors has authority as Plan Administrator of our 1993 Stock Option Plan to provide for the accelerated vesting of the shares of common stock subject to outstanding options held by the Chief Executive Officer and other executive officers, whether granted under that plan or any predecessor plan, in the event their employment were to be terminated (whether involuntarily or through a forced resignation) following (i) an acquisition by merger or asset sale, or (ii) a hostile takeover effected through a successful tender offer for more than 50% of our outstanding common stock or through a change in the majority of the Board as a result of one or more contested elections for Board membership.

The members of the Compensation Committee of our Board of Directors are Andrew J. Perlman, Vincent Worms and Elizabeth Greetham. No member of the Committee was at any time during the 1999 fiscal year or at any other time an officer or employee of SangStat or a subsidiary.

Dr. Philippe Pouletty served as our Chief Executive Officer from 1995 until February 1999, and currently serves as the Chairman of our Board of Directors. Dr. Pouletty is also the Chief Executive Officer and Chairman of the Board of Directors of DrugAbuse Sciences, Inc. Ms. Elizabeth Greetham has served on our Compensation Committee since September 1996, and is also the Chief Financial Officer of DrugAbuse Sciences, Inc.

The following table sets forth certain information known to us with respect to the beneficial ownership of our common stock as of April 14, 2000 by (i) all persons who are beneficial owners of five percent (5%) or more of our common stock, (ii) each director and nominee for director, (iii) the Named Executive Officers, and (iv) all directors and executive officers as a group as of April 14, 2000. Unless otherwise indicated, each of the stockholders has sole voting and investment power with respect to the shares beneficially owned, subject to community property laws, where applicable.

We entered into an agreement with Abbott Laboratories in May 1999 for the co-promotion, distribution, and clinical development in the United States of our SangCya Oral Solution and a cyclosporine capsule product. Under this agreement we will share marketing and promotional expenses as well as the profits from the co-promotion of these two products. The agreement ends December 31, 2004 unless we both agree to extend it. As part of the agreement, Abbott purchased 895,000 shares of our common stock for approximately $14 million representing a premium to fair market value of approximately $1.3 million, loaned us $16 million and made milestone payments totaling $13.9 million as of December 31, 1999. The loan bears interest at 8.75%, payable annually, and is secured by a security interest in the United States marketing rights for SangCya Oral Solution. The loan matures on December 31, 2004, and can be prepaid by us without penalty at any time prior to maturity. .As a result of their equity investment, Abbott now holds approximately five percent (5%) of our outstanding common stock. In connection with this equity investment we also agreed to register the SangStat shares Abbott purchased upon Abbott's request after November 15, 2001. Abbott has agreed not to re-sell any of these shares prior to December 31, 2001. After this time and until December 31, 2004 we have a right of first refusal on any resales of these shares by Abbott at the price at which Abbott proposes to sell them. We also have the right to repurchase these shares from Abbott at any time prior to December 31, 2001 at a price equal to twice what Abbott paid for them.

As of December 31, 1999, loans were outstanding to us in the principal amount of $200,000 from Mr. Bienaimé, $200,000 from Dr. Tesi and $30,000 from Dr. Winter, all of whom are executive officers. We made these loans to these officers to provide housing assistance as part of their relocation packages. We made Mr. Bienaimé's loan in July 1998, Dr. Tesi's loan in September 1997 and Dr. Winter's loan in June 1997. Each such loan is evidenced by a promissory note secured by options to purchase shares of our common stock. Neither Mr. Bienaimé, Dr. Tesi nor Dr. Winter has repaid any principal amounts or interest due on their loans, which are due on July 17, 2001, September 12, 2000 and June 5, 2000, respectively. The annual interest rates on the loans are as follows: Mr. Bienaimé 5.69%, Dr. Tesi 6.0% and Dr. Winter 5.95%. At December 31, 1999, the aggregate indebtedness of Mr. Bienaimé, Dr. Tesi and Dr. Winter under such loans was $216,883, $228,783 and $34,818, respectively, including principal and accrued interest. The amounts owed under these loans as of April 14, 2000 was $220,343, $232,662 and $35,394, respectively.

All future transactions, including loans, between us and our officers, directors, principal stockholders and their affiliates will be approved by a majority of the Board, including a majority of the independent and disinterested directors.

Each director has entered into an indemnification agreement with us. These agreements, among other things, require us to indemnify each director to the fullest extent permitted by Delaware law, including indemnification for expenses such as attorneys' fees, judgments, fines and settlement amounts incurred by the director in any action or proceeding, including any action by or in the right of us, arising out of the person's services as a director, any subsidiary or any other company or enterprise to which the person provides services at our request.

Dated: May 1, 2000

	SANGSTAT MEDICAL CORPORATION

	By:	/s/ JEAN-JACQUES BIENAIME

	Jean-Jacques Bienaime, President and Chief Executive Officer